Safety, Tolerability and Immunogenicity Study of Different Vaccine Regimens of Trivalent Ad26.Mos.HIV or Tetravalent Ad26.Mos4.HIV Along With Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults
Clinical trial NCT02788045 · COMPLETED
Trial details
- NCT number
- NCT02788045
- Sponsor
- Janssen Vaccines & Prevention B.V.
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-07-08
- Primary completion
- 2022-04-25
- Enrollment
- 201
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.